Can Zevra Therapeutics (ZVRA) Turn Clinical Momentum Into Sustainable Competitive Advantage? [Yahoo! Finance]
Zevra Therapeutics, Inc. (ZVRA)
Company Research
Source: Yahoo! Finance
investigators discussed new clinical data on its approved therapy MIPLYFFA (arimoclomol) for Niemann-Pick disease type C. A unique aspect highlighted was that MIPLYFFA, in combination with miglustat, is currently the only treatment shown to halt disease progression by addressing the underlying pathology of Niemann-Pick disease type C with a durable effect, according to clinical studies involving more than 270 patients worldwide. We'll look at how MIPLYFFA's new clinical evidence and European regulatory momentum impact the investment narrative for Zevra Therapeutics. Find companies with promising cash flow potential yet trading below their fair value Zevra Therapeutics Investment Narrative Recap Anyone considering Zevra Therapeutics must believe in the company's ability to drive sustained growth from rare disease therapies, primarily through MIPLYFFA's uptake in the US and eventual expansion in Europe. The recent presentation of robust new clinical data at the International N
Show less
Read more
Impact Snapshot
Event Time:
ZVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZVRA alerts
High impacting Zevra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ZVRA
News
- Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhDGlobeNewswire
- Zevra Therapeutics, Inc. Announces CFO Transition [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics announces CFO transition [Seeking Alpha]Seeking Alpha
- Zevra Therapeutics, Inc. Announces CFO TransitionGlobeNewswire
- Analysts Have Lowered Expectations For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Latest Results [Yahoo! Finance]Yahoo! Finance
ZVRA
Earnings
- 11/5/25 - Beat
ZVRA
Sec Filings
- 12/2/25 - Form 8-K
- 11/20/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- ZVRA's page on the SEC website